PB2051: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC/EFFICACY MODELING OF SB12 (PROPOSED ECULIZUMAB BIOSIMILAR) AND REFERENCE ECULIZUMAB

PB2051: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC/EFFICACY MODELING OF SB12 (PROPOSED ECULIZUMAB BIOSIMILAR) AND REFERENCE ECULIZUMAB

Bibliographic Details
Main Authors:	Hyuna Lee, Jihye Park, Hyerin Jang, Jungryul Kim
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000975004.91980.ef

Similar Items

A phase III, randomised, double‐blind, multi‐national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria
by: Jun Ho Jang, et al.
Published: (2023-02-01)

P829: A PHASE III RANDOMIZED CLINICAL TRIAL COMPARING SB12 (PROPOSED ECULIZUMAB BIOSIMILAR) WITH REFERENCE ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
by: J. H. Jang, et al.
Published: (2022-06-01)

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
by: Jonathan P. R. Monteleone, et al.
Published: (2021-11-01)

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder
by: Pratap Singh, et al.
Published: (2021-11-01)

P815: PHARMACOKINETIC AND PHARMACODYNAMIC SIMILARITY OF ABP 959 AND ECULIZUMAB REFERENCE PRODUCT: UNBOUND ECULIZUMAB AND CH50 FROM THE RANDOMIZED, DOUBLE-BLIND, SINGLE-DOSE STUDY IN HEALTHY VOLUNTEERS
by: V. Hanes, et al.
Published: (2022-06-01)

In-Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period
by: Minji Tak, et al.
Published: (2023-08-01)

Results of phase Ib open multicenter clinical trial of the safety, pharmacokinetics and pharmacodynamics of first biosimilar of eculizumab in untreated patients with paroxysmal nocturnal hemoglobinuria during induction of therapy
by: V. V. Ptushkin, et al.
Published: (2020-09-01)

Eculizumab in kidney diseases
by: Fatemeh Pour-Reza-Gholi, et al.
Published: (2024-01-01)

Paroxysmal nocturnal hemoglobinuria and eculizumab
by: Lucio Luzzatto, et al.
Published: (2010-04-01)

Aplicaciones terapéuticas del eculizumab
by: Natalia Campos-González, et al.
Published: (2022-04-01)

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
by: Romy N. Bouwmeester, et al.
Published: (2021-01-01)

The experience of using the Russian biosimilar of the original drug eculizumab for the treatment of patients with atypical hemolytic-uremic syndrome
by: Yulia V. Lavrishcheva, et al.
Published: (2020-07-01)

Eculizumab as Additional Rescue Therapy in Myasthenic Crisis
by: Francesco Crescenzo, et al.
Published: (2024-02-01)

The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
by: Jihad Ben Gabr MD, et al.
Published: (2020-08-01)

Comparing the original and biosimilar biotherapeutics of the monoclonal antibody eculizumab by intact mass measurement and middle-up mass spectrometry analysis
by: M. B. Degterev, et al.
Published: (2021-03-01)

Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre
by: Maximilien Grall, et al.
Published: (2021-07-01)

Eculizumab treatment alters the proteometabolome beyond the inhibition of complement
by: Christopher Nelke, et al.
Published: (2023-07-01)

Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
by: Palma LMP, et al.
Published: (2016-04-01)

Atypical hemolytic uremic syndrome and eculizumab therapy in children
by: Seong Heon Kim, et al.
Published: (2018-02-01)

Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
by: Sara Madureira Gomes, et al.
Published: (2021-04-01)

Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis
by: Hai Xiao, et al.
Published: (2021-08-01)

Fulminant Acute Ascending Hemorrhagic Myelitis Treated with Eculizumab
by: Nang Boe Ohnmar Hsam, et al.
Published: (2017-07-01)

Transplant-associated Thrombotic Microangiopathy Treated with Eculizumab and Romiplostim
by: Muhammad Awidi, et al.
Published: (2021-02-01)

Hemoglobinuria paroxística nocturna: de Strübing al Eculizumab
by: Ivis Macía Pérez, et al.

Similar pharmacokinetics and pharmacodynamics of a new biosimilar and reference insulin aspart in healthy Chinese males
by: Hui Liu, et al.
Published: (2021-05-01)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
by: Pittock, S, et al.
Published: (2019)

Meningococcemia in a vaccinated child receiving eculizumab and review of the literature
by: Diana Üçkardeş, et al.
Published: (2023-02-01)

Treatment of Shiga-Toxin Hus with Severe Neurologic Features with Eculizumab
by: Jacob H. Umscheid, et al.
Published: (2021-01-01)

Method development and validation for determination of antihemolytic activity of eculizumab (Soliris)
by: E. Yu. Prudnikova, et al.
Published: (2017-03-01)

Case report: Timing of eculizumab treatment in catastrophic antiphospholipid syndrome
by: Camillo Carrara, et al.
Published: (2024-09-01)

Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease
by: Satheesh Chonat, et al.
Published: (2020-07-01)

Rational use of eculizumab in secondary atypical hemolytic uremic syndrome
by: Lucía Cordero, et al.
Published: (2024-01-01)

Rapid Resolution of Atypical Hemolytic Uremic Syndrome by Eculizumab Treatment
by: Min Seung Kim, et al.
Published: (2020-10-01)

Eculizumab‐related drug reaction in a patient with neuromyelitis optica
by: Rishi Sharma, et al.
Published: (2023-02-01)

Eculizumab for bevacizumab induced thrombotic microangiopathy: A case report
by: Mihriban İnözü, et al.
Published: (2022-12-01)

Eculizumab experience in an adult patient with atypical hemolytic uremic syndrome
by: Funda Sari, et al.
Published: (2017-01-01)

Treatment of Aggressive Antineutrophil Cytoplasmic Antibody–Associated Vasculitis With Eculizumab
by: Noah Huizenga, et al.
Published: (2020-04-01)

Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
by: Valentina Vélez-Santamaría, et al.
Published: (2020-06-01)

Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis
by: Munenori Oyama, et al.
Published: (2020-03-01)

Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome
by: Saritha Ranabothu, et al.
Published: (2021-10-01)